Alnylam Pharmaceuticals Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Alnylam Pharmaceuticals Inc 公司

Alnylam Pharmaceuticals, Inc. 是一家商業階段的生物製藥公司。該公司致力於發現、開發、製造和商業化基於核糖核酸干擾 (RNAi) 的新型療法。其上市產品包括用於治療成人遺傳性轉甲狀腺素介導性澱粉樣變性 (hATTR) 伴多發性神經病的 AMVUTTRA (vutrisiran)；用於治療成人 hATTR 澱粉樣變性伴多發性神經病的 ONPATTRO (patisiran)；用於治療成人急性肝卟啉症的 GIVLAARI (givosiran)；用於治療 1 型原發性高草酸尿症的 OXLUMO (lumasiran)，以及由其合作伙伴諾華公司開發和商業化的 Leqvio (inclisiran)，用於治療成人高膽固醇血癥或混合性血脂異常。該公司的臨牀開發項目包括 Cemdisiran、Fitusiran、Zilebesiran、Elebsiran、Mivelsiran 和 ALN-HTT02。該公司正在開發 Cemdisiran 來治療補體介導的疾病。

Alnylam Pharmaceuticals Inc簡介



公司代碼ALNY

公司名稱Alnylam Pharmaceuticals Inc

上市日期May 28, 2004

CEODr. Yvonne L. Greenstreet, M.D.

員工數量2230

證券類型Ordinary Share

年結日May 28

公司地址675 W Kendall St

城市CAMBRIDGE

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編02142-1168

電話16175518200

網址https://www.alnylam.com/

公司代碼ALNY

上市日期May 28, 2004

CEODr. Yvonne L. Greenstreet, M.D.

Alnylam Pharmaceuticals Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

65.82K

+16.23%

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

54.11K

+7.83%

Mr. Tolga Tanguler

Chief Commercial Officer

27.44K

+5.56%

Mr. Michael W. (Mike) Bonney

Chief Compliance Officer, Director

20.80K

--

Dr. Dennis A. Ausiello, M.D.

Independent Director

4.41K

--

Dr. Margaret A. Hamburg, M.D.

Independent Director

911.00

+569.85%

Ms. Carolyn R. Bertozzi, M.D.

Independent Director

775.00

--

Dr. Olivier Brandicourt, M.D.

Independent Director

775.00

--

Mr. Peter N. Kellogg

Independent Director

775.00

--

Ms. Colleen F. Reitan

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

65.82K

+16.23%

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

54.11K

+7.83%

Mr. Tolga Tanguler

Chief Commercial Officer

27.44K

+5.56%

Mr. Michael W. (Mike) Bonney

Chief Compliance Officer, Director

20.80K

--

Dr. Dennis A. Ausiello, M.D.

Independent Director

4.41K

--

Dr. Margaret A. Hamburg, M.D.

Independent Director

911.00

+569.85%

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

業務USD

名稱

營收

佔比

AMVUTTRA

491.95M

63.59%

GIVLAARI

80.85M

10.45%

ONPATTRO

52.54M

6.79%

Other

50.67M

6.55%

OXLUMO

46.87M

6.06%

其他

50.81M

6.57%

地區USD

名稱

營收

佔比

United States

454.57M

58.75%

Europe

157.01M

20.29%

Net revenues from collaborations

61.50M

7.95%

Rest of World

60.63M

7.84%

Royalty revenue

39.98M

5.17%

業務

地區

業務USD

名稱

營收

佔比

AMVUTTRA

491.95M

63.59%

GIVLAARI

80.85M

10.45%

ONPATTRO

52.54M

6.79%

Other

50.67M

6.55%

OXLUMO

46.87M

6.06%

其他

50.81M

6.57%

股東統計

更新時間: 8月16日週六

持股股東

股東類型

持股股東

佔比

Capital World Investors

12.72%

Fidelity Management & Research Company LLC

11.39%

The Vanguard Group, Inc.

10.22%

Capital Research Global Investors

5.44%

BlackRock Institutional Trust Company, N.A.

4.94%

其他

55.28%

持股股東

佔比

Capital World Investors

12.72%

Fidelity Management & Research Company LLC

11.39%

The Vanguard Group, Inc.

10.22%

Capital Research Global Investors

5.44%

BlackRock Institutional Trust Company, N.A.

4.94%

其他

55.28%

股東類型

持股股東

佔比

Investment Advisor

68.97%

Investment Advisor/Hedge Fund

21.97%

Hedge Fund

3.70%

Research Firm

1.84%

Sovereign Wealth Fund

1.63%

Bank and Trust

1.27%

Pension Fund

1.27%

Corporation

1.05%

Individual Investor

0.42%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

1364

130.85M

99.04%

-1.89M

2025Q2

1300

131.78M

100.54%

-3.28M

2025Q1

1315

132.55M

101.67%

-2.42M

2024Q4

1263

130.73M

100.99%

-1.47M

2024Q3

1225

126.90M

98.51%

-1.26M

2024Q2

1183

123.30M

96.32%

+1.12M

2024Q1

1172

117.88M

93.23%

-5.46M

2023Q4

1169

120.70M

96.18%

-5.54M

2023Q3

1125

121.55M

96.89%

-6.15M

2023Q2

1119

122.11M

98.30%

-6.32M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Capital World Investors

16.81M

12.82%

+55.38K

+0.33%

Jun 30, 2025

Fidelity Management & Research Company LLC

15.05M

11.48%

+427.38K

+2.92%

Jun 30, 2025

The Vanguard Group, Inc.

13.24M

10.1%

+238.24K

+1.83%

Jun 30, 2025

Capital Research Global Investors

7.19M

5.49%

+36.93K

+0.52%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

6.53M

4.98%

-199.00K

-2.96%

Jun 30, 2025

T. Rowe Price Investment Management, Inc.

4.28M

3.27%

-136.87K

-3.10%

Jun 30, 2025

JP Morgan Asset Management

1.79M

1.37%

-87.08K

-4.64%

Jun 30, 2025

Dodge & Cox

3.20M

2.44%

-154.67K

-4.61%

Jun 30, 2025

State Street Investment Management (US)

3.17M

2.42%

-193.48K

-5.75%

Jun 30, 2025

T. Rowe Price Associates, Inc.

3.05M

2.32%

-359.26K

-10.55%

Jun 30, 2025

持股ETF



更新時間: 11月6日週四

機構名稱

佔比

Global X Genomics & Biotechnology ETF

6.7%

ProShares Ultra Nasdaq Biotechnology

6.12%

Invesco Nasdaq Biotechnology ETF

5.99%

iShares Biotechnology ETF

5.42%

Franklin Genomic Advancements ETF

5.21%

VanEck Biotech ETF

4.84%

First Trust NYSE Arca Biotechnology Index Fund

4.5%

American Century Focused Dynamic Growth ETF

4.11%

Pinnacle Focused Opportunities ETF

3.71%

Invesco NASDAQ Next Gen 100 ETF

3.42%

Global X Genomics & Biotechnology ETF

佔比6.7%

ProShares Ultra Nasdaq Biotechnology

佔比6.12%

Invesco Nasdaq Biotechnology ETF

佔比5.99%

iShares Biotechnology ETF

佔比5.42%

Franklin Genomic Advancements ETF

佔比5.21%

VanEck Biotech ETF

佔比4.84%

First Trust NYSE Arca Biotechnology Index Fund

佔比4.5%

American Century Focused Dynamic Growth ETF

佔比4.11%

Pinnacle Focused Opportunities ETF

佔比3.71%

Invesco NASDAQ Next Gen 100 ETF

佔比3.42%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據